Chilimoniuk Małgorzata, Olszewska Ewa, Maksimowicz Tomasz
Department of Radiotherapy II, Oncology Center in Bialystok, Poland.
Pol Merkur Lekarski. 2010 Dec;29(174):357-60.
The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies. Results of treatment for locally advanced squamous cell head and neck cancer with surgery and/or radiotherapy are still unsatisfactory. During last decade concomitant chemoradiotherapy became a new standard in this group of patients. The treatment method is charged of high toxicity and real therapeutic advantages are obtained by limited number of patients. Intensive clinical investigations on novel therapeutic strategies are in progress. One of them is the combination of induction chemotherapy with taxan (TPF) and concomitant chemoradiotherapy join with cisplatin. The aim of the study was to estimate the treatment tolerance and early term results with combination of induction chemotherapy with TPF and concomitant chemoradiotherapy join with cisplatin in patients with locally advanced, squamous cell carcinoma of head and neck.
Patients with locally advanced oropharyngeal and larynx cancer treated in the Institute of Oncology in Bialystok at the Department of Radiotherapy II from latter half of 2009 year were included in the study. The treatment protocol consisted of 3 courses of induction chemotherapy TPF (Taxotere 75 mg/m2, DDP 100 mg/m2, 5-Fluorouracyl 1000 mg/m2 every 3 weeks) and conventionally fractionated radiotherapy (Df=2 Gy, 5 x weekly) to total dose of 66-72 Gy and for neck cervical lymph nodes up to 60-66 Gy with concomitant of cisplatin 100 mg/m2 every 3 weeks. Early reactions were estimated according to EORTC/RTOG scales, and chemotherapy tolerance was evaluated according to the CTC scale. Twelve patients with homogenous criteria were included in the study.
The treatment tolerance was acceptable. However several adverse reactions were present. The main adverse effect was the extensive mucosal reaction. Neutropenia and anemia were also observed in most of the patients. Some patients complained of diarrhea, vomiting and nausea in mild or moderate intensity which were persisted temporarily.
Induction chemotherapy TPF and concomitant radiochemotherapy with cisplatin in patients with locally advanced head and neck cancer in III-IV clinical stages came out as the treatment of high efficacy.
头颈部癌患者数量的不断增加促使人们寻找新的有效治疗策略。局部晚期头颈部鳞状细胞癌采用手术和/或放疗的治疗效果仍不尽人意。在过去十年中,同步放化疗成为了这类患者的新标准治疗方法。该治疗方法毒性较大,且只有少数患者能获得实际的治疗优势。针对新型治疗策略的深入临床研究正在进行。其中之一是诱导化疗联合紫杉烷(TPF)以及同步放化疗联合顺铂。本研究的目的是评估诱导化疗联合TPF以及同步放化疗联合顺铂治疗局部晚期头颈部鳞状细胞癌患者的治疗耐受性和早期疗效。
2009年下半年在比亚韦斯托克肿瘤研究所放疗二科接受治疗的局部晚期口咽癌和喉癌患者被纳入本研究。治疗方案包括3个疗程的诱导化疗TPF(多西他赛75mg/m²、顺铂100mg/m²、5-氟尿嘧啶1000mg/m²,每3周一次),以及常规分割放疗(分割剂量=2Gy,每周5次),总剂量达66 - 72Gy,颈部淋巴结剂量达60 - 66Gy,同时每3周给予顺铂100mg/m²。根据欧洲癌症研究与治疗组织(EORTC)/美国放射肿瘤学会(RTOG)标准评估早期反应,根据癌症治疗毒性标准(CTC)评估化疗耐受性。12例符合统一标准的患者被纳入研究。
治疗耐受性尚可。然而,出现了一些不良反应。主要不良反应是广泛的黏膜反应。大多数患者还出现了中性粒细胞减少和贫血。一些患者抱怨有轻度或中度的腹泻、呕吐和恶心,这些症状暂时持续存在。
对于III - IV期临床阶段的局部晚期头颈部癌患者,诱导化疗TPF以及同步放化疗联合顺铂是一种高效的治疗方法。